Methods for diagnosis, prognosis and methods of treatment

A method of correlating and/or classifying an activation state of a CLL cell with a clinical outcome in an individual by:

• (i) subjecting the CLL cell from the individual to a modulator, where the CLL cell expresses a B-Cell receptor (BCR);
• (ii) determining the activation levels of a plurality of activatable elements;
• and
• (ii) identifying a pattern of the activation levels of the plurality of activatable elements to determine the presence or absence of an alteration in signaling proximal to BCR, where the presence of the alteration is indicative of a clinical outcome.

A method of classifying a cell population by

• (i) contacting the cell population with at least one modulator, wherein the modulator comprises F(ab)2 IgM, an anti-CD20 antibody, an anti-CD52 antibody, an anti-CD22 antibody, an anti-CD23 antibody, bendamustine, velcade, phenylarsine oxide, sodium vanadate, H2O2, PMA, BAFF, April, SDF1a, CD40L, IGF-1, Imiquimod, polyCpG, fludarabine, cyclophosphamide, chlorambucil, IL-7, IL-6, IL-10, IL-27, IL-4, IL-2, IL-3, thapsigargin or a combination thereof;
• (ii) determining the presence or absence of an increase in activation level of an activatable element in the cell population;
• and
• (iii) classifying the cell population based on the presence or absence of the increase in the activation of the activatable element.